Brief: Ardelyx Shares Preliminary Data On Use Of Ibsrela® (Tenapanor) In Pediatric Ibs-C Patients
04/10/2023 13:05
Oct 4 (Reuters) - Ardelyx Inc ARDX.O :
* ARDELYX SHARES PRELIMINARY DATA ON USE OF IBSRELA®
(TENAPANOR)
IN PEDIATRIC IBS-C PATIENTS AT NASPGHAN 2023
Source text for Eikon: ID:nGNX8qGjHc
Further company coverage: ARDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ardelyx
See all newsArdelyx, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectations
Brief: Ardelyx Q2 Product Sales USD 118.129 Million
Ardelyx Q1 product revenue rises 38% on IBSRELA growth
Brief: Ardelyx Q1 Product Sales USD 93.373 Million